ScreenerHero

PMN ProMIS Neurosciences, Inc.

NAS · US · Healthcare · Biotechnology · promisneurosciences.com
9.120USD-0.98%Mkt Cap: 81.79M $P/E: —

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform co…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap81.79M USD
Enterprise Value29.13M USD
Revenue (TTM)—
Gross Profit-35.66M USD
Net Income (TTM)-39.72M USD
Revenue/Share—
Last Price9.120 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.03
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.67
EPS (TTM)-11.61
EPS (Forward)-4.53
52W Range
6.27013% of range27.40
52W High27.40 USD
52W Low6.270 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE3155.84%
ROA-432.56%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.12M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-32.81%
Net Debt-53.46M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio7.86
Quick Ratio7.44
Book Value/Sh5.51 USD
Cash/Share5.96 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateNov 28, 2025
Analyst Consensus
Rating—
Target (Mean)42.64 USD
Upside (mean)+367.6%
Target Range17.80 USD – 98.08 USD
17.80+367.6% to mean98.08
# Analysts7
Ownership
Shares Out.8.97M
Float4.38M
Insiders11.87%
Institutions77.20%
Short Interest
Short Ratio6.2d
Short % Float2.69%
Short % Out.2.68%
Shares Short240.00K
Short (prev mo.)281.13K
Technical
SMA 5013.35 (-31.7%)
SMA 20012.82 (-28.8%)
Beta-0.25
S&P 52W Chg15.78%
Avg Vol (30d)39.05K
Avg Vol (10d)43.30K
Technical Indicators
RSI (14)28.7
MACD-1.2005
MACD Signal-0.8909
MACD Hist.-0.3096
BB Upper15.32 USD
BB Middle11.73 USD
BB Lower8.137 USD
BB Width61.25%
ATR (14)0.9874 USD
Vol Ratio (20d)0.60x